DK0920873T3 - Stabiliserede teriparatidoplösninger - Google Patents

Stabiliserede teriparatidoplösninger

Info

Publication number
DK0920873T3
DK0920873T3 DK98123225T DK98123225T DK0920873T3 DK 0920873 T3 DK0920873 T3 DK 0920873T3 DK 98123225 T DK98123225 T DK 98123225T DK 98123225 T DK98123225 T DK 98123225T DK 0920873 T3 DK0920873 T3 DK 0920873T3
Authority
DK
Denmark
Prior art keywords
stabilized teriparatide
solutions
teriparatide solutions
stabilized
teriparatide
Prior art date
Application number
DK98123225T
Other languages
Danish (da)
English (en)
Inventor
Chin-Ming Chang
Henry A Havel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0920873(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0920873T3 publication Critical patent/DK0920873T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
DK98123225T 1997-12-09 1998-12-07 Stabiliserede teriparatidoplösninger DK0920873T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09

Publications (1)

Publication Number Publication Date
DK0920873T3 true DK0920873T3 (da) 2004-06-28

Family

ID=22086574

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03104219.5T DK1417972T4 (en) 1997-12-09 1998-12-07 Stabilized teriparatide solutions
DK98123225T DK0920873T3 (da) 1997-12-09 1998-12-07 Stabiliserede teriparatidoplösninger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03104219.5T DK1417972T4 (en) 1997-12-09 1998-12-07 Stabilized teriparatide solutions

Country Status (32)

Country Link
EP (2) EP0920873B1 (ru)
JP (1) JP4405666B2 (ru)
KR (1) KR100482703B1 (ru)
CN (1) CN1198644C (ru)
AR (1) AR018526A1 (ru)
AT (1) ATE260113T1 (ru)
AU (1) AU759726B2 (ru)
BR (1) BR9813463A (ru)
CA (1) CA2314313C (ru)
CY (1) CY1114000T1 (ru)
CZ (1) CZ302401B6 (ru)
DE (1) DE69821872T2 (ru)
DK (2) DK1417972T4 (ru)
EA (1) EA004761B1 (ru)
EG (1) EG23675A (ru)
ES (2) ES2405994T5 (ru)
HK (1) HK1021798A1 (ru)
HU (1) HU230784B1 (ru)
ID (1) ID27741A (ru)
IL (1) IL136662A (ru)
MY (1) MY120063A (ru)
NO (1) NO327302B1 (ru)
NZ (1) NZ505222A (ru)
PE (1) PE20000001A1 (ru)
PL (1) PL194268B1 (ru)
PT (2) PT920873E (ru)
SK (1) SK288203B6 (ru)
TR (1) TR200002134T2 (ru)
TW (1) TW570811B (ru)
UA (1) UA72884C2 (ru)
WO (1) WO1999029337A1 (ru)
ZA (1) ZA9811127B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776823B2 (en) * 1998-07-23 2004-09-23 Ares Trading S.A. FSH and FSH variant formulations, products and methods
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
CA2380423A1 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
JP2004513069A (ja) * 2000-05-19 2004-04-30 レストラゲン,インコーポレイテッド ペプチド医薬処方
US20040156835A1 (en) * 2001-05-30 2004-08-12 Taiji Imoto Protein preparation
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
AU2002363412A1 (en) * 2001-11-05 2003-05-19 Eli Lilly And Company Method for improving stability of a bone-connecting implant
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
DK1610822T4 (en) 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
CA2526099C (en) 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
CN113304250A (zh) 2003-11-20 2021-08-27 诺和诺德股份有限公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물
CA2628945A1 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
DK2957278T3 (en) * 2006-10-03 2017-07-31 Radius Health Inc STABLE COMPOSITION COMPREHENSIVE PTHRP AND APPLICATIONS THEREOF
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
WO2008150929A1 (en) * 2007-05-29 2008-12-11 Manhattan Pharmaceuticals, Inc. Topical compositions comprising a macromolecule and methods of using same
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
ES2586032T3 (es) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administración de composiciones de benzodiazepinas
JP5583680B2 (ja) 2008-10-15 2014-09-03 インフィニティー ファーマスーティカルズ インコーポレイテッド アンサマイシンヒドロキノン組成物
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
KR102424644B1 (ko) * 2009-09-09 2022-07-25 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 pth가 주 1회 투여되는 것을 특징으로 하는, pth 함유 골다공증 치료/예방제
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012174158A2 (en) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration of benzodiazepine
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
RU2737496C2 (ru) 2015-04-29 2020-12-01 Радиус Фармасьютикалз, Инк. Способы лечения рака
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
CN115025239A (zh) 2016-03-01 2022-09-09 阿森迪斯药物骨疾病股份有限公司 Pth前药
AU2017336249B2 (en) 2016-09-29 2024-08-01 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release PTH compound
AU2017336251B2 (en) 2016-09-29 2024-02-22 Ascendis Pharma Bone Diseases A/S PTH compounds with low peak-to-trough ratios
FI3565542T3 (fi) 2017-01-05 2024-06-24 Radius Pharmaceuticals Inc Rad1901-2hcl:n polymorfisia muotoja
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
CN111032073A (zh) * 2017-09-22 2020-04-17 旭化成制药株式会社 药物动力学和/或安全性优异的含有特立帕肽的液态药物组合物
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
WO2019220654A1 (ja) * 2018-05-17 2019-11-21 旭化成ファーマ株式会社 N-ホルミルピぺリジン含有量が低減されている、及び/又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
WO2020165087A1 (en) * 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 h―PTH(1―34)凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
WO1993011785A1 (en) * 1991-12-09 1993-06-24 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
DK1417972T3 (da) 2013-05-13
KR20010032881A (ko) 2001-04-25
TR200002134T2 (tr) 2000-11-21
DK1417972T4 (en) 2018-10-22
ID27741A (id) 2001-04-26
HK1021798A1 (en) 2000-07-07
IL136662A0 (en) 2001-06-14
NZ505222A (en) 2003-05-30
NO20002945L (no) 2000-07-07
JP2001525372A (ja) 2001-12-11
EP0920873A2 (en) 1999-06-09
HUP0004447A3 (en) 2003-06-30
HUP0004447A2 (hu) 2001-04-28
HU230784B1 (en) 2018-05-02
ZA9811127B (en) 2000-07-11
UA72884C2 (ru) 2005-05-16
DE69821872D1 (de) 2004-04-01
TW570811B (en) 2004-01-11
EP1417972B1 (en) 2013-04-10
AU759726B2 (en) 2003-04-17
SK15322000A3 (sk) 2001-05-10
ES2215268T3 (es) 2004-10-01
PL340902A1 (en) 2001-03-12
BR9813463A (pt) 2000-10-10
WO1999029337A1 (en) 1999-06-17
CA2314313A1 (en) 1999-06-17
KR100482703B1 (ko) 2005-04-14
DE69821872T2 (de) 2005-01-05
EA200000629A1 (ru) 2000-12-25
SK288203B6 (sk) 2014-07-02
CN1281370A (zh) 2001-01-24
EG23675A (en) 2007-04-15
PL194268B1 (pl) 2007-05-31
EP1417972B2 (en) 2018-08-22
EP1417972A1 (en) 2004-05-12
NO20002945D0 (no) 2000-06-08
ES2405994T5 (es) 2019-01-30
ES2405994T3 (es) 2013-06-04
CA2314313C (en) 2005-02-08
AU1717799A (en) 2005-05-16
PE20000001A1 (es) 2000-01-17
ATE260113T1 (de) 2004-03-15
CN1198644C (zh) 2005-04-27
JP4405666B2 (ja) 2010-01-27
EP0920873A3 (en) 1999-08-04
PT1417972E (pt) 2013-05-24
AR018526A1 (es) 2001-11-28
NO327302B1 (no) 2009-06-02
CZ20002115A3 (en) 2001-05-16
CZ302401B6 (cs) 2011-05-04
MY120063A (en) 2005-08-30
CY1114000T1 (el) 2016-07-27
EA004761B1 (ru) 2004-08-26
PT920873E (pt) 2004-06-30
EP0920873B1 (en) 2004-02-25
IL136662A (en) 2004-09-27

Similar Documents

Publication Publication Date Title
DK1417972T3 (da) Stabiliserede teriparatidopløsninger
NO20003131D0 (no) Krystallinsk teriparatid
ID22500A (id) Turunan sulfonamida
DE69826749D1 (de) Stabilisierte Persäurelösungen
ID24430A (id) Turunan-turunan benzamidina
NO2006014I1 (no) Insulin glulisin
ID24529A (id) Turunan-turunan 9-oksima eritromisin
FI973171A0 (fi) Foerfarande foer drift av arbetsfartyg
DE59804393D1 (de) Luftleiteinrichtung
DE69815673D1 (de) Stabilisierte hydroxylaminlösungen
IT1304161B1 (it) Stiratoio
ID20897A (id) Susunan penutup-rapat
FI973961A0 (fi) Lyft- och belastningsanordning foer en valsstapel i en kalander
DE69734891D1 (de) Ausrichtvorrichtung
FI972138A0 (fi) Returtraog i bestrykningsanordning
FR2770103B1 (fr) Bigoudi perfectionne
ID21138A (id) Teknologi film-tipis untuk head-drum
KR980001295U (ko) 개량 도장
FI974242A0 (fi) Formframstaellning av plywoodprofil i kontinuerlig drift
FI972751A (fi) Ääntä hajottava soladiffusorirakenne
BR7700789U (pt) Prumo
FI972640A0 (fi) Gapformare i en pappersmaskin/kartongmaskin
BR9701099A (pt) Acertrol i
FI974354A0 (fi) Kvaevereducering i avloppsvatten
FI974373A0 (fi) Avgasutlopp i utombordsmotorer